Agoracom Blog

AGORACOM Small-Cap TV – 6 Great Press Releases At The Open (March 6th)

Posted by AGORACOM at 9:23 AM on Thursday, March 6th, 2008

Good morning to you all. Please find enclosed a summary of the great small-cap and micro-cap press releases we highlighted on our TV show this morning. It’s March 6th and we’ve found 6 great press release from both sides of the border to report on at the open. Another great day for the small-cap and micro-cap world.

You can watch AGORACOM TV right from our home page , or our archive where you can see or search all of our previous shows.

If you are new to the show, it is a daily, fast-paced, edgy report that we put out at or before the open everyday that strictly reports on the best small cap and micro cap press releases of the day in 3-5 minutes. You can watch the show by going to AGORACOM every morning.

Our daily show focuses on content over form so that you can get profitable information into your hands as fast as possible. The same holds true for these blog entries where I simply cut and paste my TV notes for your benefit, without any editing.

If you have any material information pertaining to any of today’s companies, be sure to share your knowledge by posting your comments for everyone to see.

As always, don’t forget to visit the AGORACOM Marketplace where we list compelling summaries for over 65 great small-cap companies that you can sort by exchange and industry to suit your personal investing tastes.

Now, onto our show notes for the day.


Lexaria Corp. (OTC BB:LXRA.OB)

Q1 Revenues Increase and Companies Goes Cash Flow Positive

announce an increase in revenues for the first fiscal quarter ending January 31, 2008 and has for the first time generated positive cash flow.

  • Revenues Increase as a result of Increased Oil & Gas Production

  • For the three months ending January 31, 2008, Lexaria recorded revenue of $354,340 compared to just $21,127 in the quarter ending January 21, 2007. The increase in revenue is due to increased oil and natural gas production and is evidence of Lexaria’s sensible business plan that has concentrated on building a sustainable business and operating company.
  • revenues for the first fiscal quarter ending January 31, 2008 and has for the first time generated positive cash flow.

President Chris Bunka said, “While our absolute numbers are still small, I’ve always been confident that we would turn cash flow positive and begin to generate a gross profit. Lexaria is growing rapidly and I expect to exit 2008 at far higher production and revenue rates than we began the year. This is the year that we grow our cash flows to a sufficient degree to allow us to reinvest and accelerate our growth.”

During the rest of 2008,

· Lexaria’s focus will be first on the low-risk development of the Belmont Lake oil field, where it believes much larger increases in oil production are possible.

· Additional exploration wells will also be drilled on and near the 32,000 acre Palmetto Point area.

During the quarter the Company produced from three oil wells in Mississippi; one oil & gas well in Oklahoma; and about nine gas wells in Mississippi. Production from most of the Mississippi wells has still not reached normalized rates and so variances in current and future production should be expected. Operations are underway to install pumps at the two Belmont Lake oil wells, which when complete should normalize production at average rates that are higher than current rates.




Reports Record 2007 Earnings

RBC Life Sciences, Inc. announced that net sales for the year-ended December 31, 2007 increased 25 percent to $27.0 million, compared to net sales of $21.7 million for the year-ended December 31, 2006.

The Company’s net earnings for 2007 improved more than 280 percent to $1.7 million, or $0.08 per diluted share, compared to net earnings of $436,000, or $0.02 per diluted share in 2006.

RBC Life Sciences develops, manufactures and markets skin care products and food supplements providing nutrients often found to be low or missing in modern diets.

MPM Medical, a wholly owned subsidiary of RBC, develops and markets proprietary prescription and nonprescription products for wound and pain management, sold through medical-surgical dealers to nursing homes, hospitals and cancer clinics.

0.94 (52 Week: 0.36 – 1.10)


Record Revenue and Net Income for 2007

today announced financial and operating results for the year ending December 31, 2007.

· The Company reported record revenues for 2007 of $7,162,329, a 33% increase over revenues of $5,403,632 for 2006. The increase is attributable to continued growth of the Company’s internet-based EDI services and revenue from products and services sold by Merkur Group, Inc. which was acquired on July 2, 2007.

· Net income for 2007 was a record $1,022,679 or $.15 per share compared to $858,670 or $.13 per share in 2006.

Advant-e Corporation a provider of Internet-based Electronic Data Interchange services and electronic document management software and services

1.95 (52 Week: 1.22 – 2.74)






Iberian Minerals Corp. (TSX VENTURE:IZN)

Provides Production Numbers From Condestable Mine

between September 30, 2007, being the effective date of the acquisition of Compania Minera Condestable S.A. (“CMC“), and December 31, 2007, the Raul mine has produced

22,160 dmt of copper concentrates containing

5,295 mt of copper,

3,814oz of gold fines

57,160oz of silver fines.

Ore Throughput Increase

The ore throughput of the processing plant has increased significantly to 5,991t/d in January 2008, close to the design level of 6,000t/d. The capacity of the plant has expanded annually since 2004, as follows:



Tyhee Development Corp. (TSX Venture, TDC)

Discovers new gold zone at Goodwin Lake Property

results from first four drill holes returning up to 14.458 gpt gold over 2.7 metres within 6.422 gpt over 6.6 metres

reports the results of the initial four drillholes on the Company’s wholly-owned Goodwin Lake Property.

all four drill holes returned significant gold values, including

6.422 grams of gold per tonne (gpt) over 6.6 metres (m) in diamond drillhole GL003,

14.458 gpt gold over 2.7 m, and 11.435 gpt over 1.5 m in diamond drillhole GL002.

Dr. D.R. Webb, President & CEO reports, “We are very pleased that the first diamond drillholes ever completed on the VAD Zone have returned such robust results. The geology was determined to be prospective, and preliminary work identified substantial zones of gold enrichment that returned very encouraging results. We feel we may have identified a new centre of mineralization that has never before been recognized.”

Tyhee has been consolidating properties in the Yellowknife Gold Belt, and has focused on internally generated prospects with significant gold potential. The results suggest the potential exists for a large tonnage Ormsby-style deposit in that the gold is hosted by a silicified, sulphidized and brecciated mafic body. The VAD Zone is 12 kilometres south of the Company’s development-stage Yellowknife Gold Project.




Reports Two Cents per Share Earnings for Three Quarters Ended January 31, 2008

a development stage biotechnology company, announced today its third quarter financial results.

· For the three months ended January 31, 2008 the Company reported net income of $611,006 and earnings per share of $0.02 compared to a net loss of $37,198 and loss of $0.00 per share for the comparable period one year ago.

· For the nine months ended January 31, 2008, the Company reported net income of $474,011 and earnings per share of $0.02 compared to a net loss of $74,086 and loss of $0.00 per share for the comparable period one year ago.

· The Company’s total operating revenues were $924,940 for the three months ended January 31, 2008 and $1,174,940 for the nine months ended January 31, 2008. The Company generated revenues for the nine months ended January 31, 2008 providing oncology services. For the three months ended January 31, 2007 and for the nine months ended January 31, 2007 the Company generated no revenues.

Champions Biotechnology Inc. is engaged in the development of advanced preclinical platforms and predictive tumor specific data to enhance and accelerate the value of oncology drugs for companies and physicians.

1.10 (52 Week: 0.26 – 2.15)





Comments are closed.